GAMMA Investing LLC lifted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 14,695.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 234,809 shares of the company's stock after buying an additional 233,222 shares during the quarter. GAMMA Investing LLC owned about 0.29% of DaVita worth $35,919,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of DVA. Epoch Investment Partners Inc. acquired a new stake in shares of DaVita during the 4th quarter worth approximately $55,100,000. Invesco Ltd. boosted its stake in DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after acquiring an additional 275,284 shares during the last quarter. Iron Triangle Partners LP bought a new position in DaVita during the 4th quarter worth approximately $38,946,000. Amundi boosted its stake in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after acquiring an additional 240,126 shares during the last quarter. Finally, Bridgewater Associates LP boosted its stake in DaVita by 298.4% during the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after acquiring an additional 179,744 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Truist Financial cut their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $164.50.
Read Our Latest Stock Report on DVA
DaVita Stock Up 0.1%
Shares of DVA stock traded up $0.21 during trading on Friday, reaching $137.95. The company's stock had a trading volume of 590,258 shares, compared to its average volume of 821,551. The business has a fifty day moving average price of $142.56 and a 200-day moving average price of $152.14. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The company has a market cap of $10.41 billion, a price-to-earnings ratio of 12.84, a price-to-earnings-growth ratio of 1.07 and a beta of 1.11. DaVita Inc. has a one year low of $131.76 and a one year high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.26 earnings per share. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
